# Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders

> **NCT06843044** · PHASE4 · RECRUITING · sponsor: **Valenta Pharm JSC** · enrollment: 250 (estimated)

## Conditions studied

- Anxiety
- Neurasthenia
- Adjustment Disorders

## Interventions

- **DRUG:** Ranquilon
- **DRUG:** Afobazole

## Key facts

- **NCT ID:** NCT06843044
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-13
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06843044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06843044, "Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06843044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*